Investigation Report on China's Raloxifene Market, 2015-2019

According to the statistics, over 200 million people suffer from osteoporosis in the world. Among women aged 50 and above in China, 50% have low bone mass or osteoporosis while this figure is 30%-50% among women aged 60 and above.

Raloxifene (raloxifene hydrochloride), a non-hormone drug against bone resorption, belongs to the second generation of selective estrogen receptor modulator (SERMs). Different from traditional estrogen replacement therapy (ERT) or hormone replacement therapy (HRT), raloxifene can not only prevent postmenopausal women from osteoporosis but also effectively increase bone mass and bone density so as to treat postmenopausal osteoporosis and prevent osteoporotic fracture.

When raloxifene made by Eli Lilly under the trade name of Evista entered the market in 1997, its global sales value in the first year reached up to 285 million, making it the second most successful product of Eli Lilly. However, raloxifene's annual sales value has been fluctuating around USD 1 billion after it reached its sales peak of USD 1.091 billion in 2007.

Raloxifene made by local enterprises came into the market after Evista entered China in Oct. 2003 and raloxifene's CAGR was about 14% during the period of 2005-2014 according to CRI's survey. Raloxifene enjoys a vast demand in China. Currently, raloxifene in the Chinese market is monopolized by the following three companies: Eli Lilly and Company (Spain), Eli Lilly and Company (UK) and Jiangsu Hengrui Medicine Co., Ltd, among of which Eli Lilly and Company (Spain) has the largest market share of 86% for sales value in 2014.

For more information visit http://www.researchandmarkets.com/research/k2h2k9/investigation

Media Contact: Laura Wood , +353-1-481-1716, [email protected]